Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic usefulness of white blood cell count and temperature in acute myocardial infarction (from the CARDINAL Trial).
Patel MR, Mahaffey KW, Armstrong PW, Weaver WD, Tasissa G, Hochman JS, Todaro TG, Malloy KJ, Rollins S, Theroux P, Ruzyllo W, Nicolau JC, Granger CB; CARDINAL Investigators. Patel MR, et al. Among authors: rollins s. Am J Cardiol. 2005 Mar 1;95(5):614-8. doi: 10.1016/j.amjcard.2004.11.008. Am J Cardiol. 2005. PMID: 15721102 Clinical Trial.
Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial.
Granger CB, Mahaffey KW, Weaver WD, Theroux P, Hochman JS, Filloon TG, Rollins S, Todaro TG, Nicolau JC, Ruzyllo W, Armstrong PW; COMMA Investigators. Granger CB, et al. Among authors: rollins s. Circulation. 2003 Sep 9;108(10):1184-90. doi: 10.1161/01.CIR.0000087447.12918.85. Epub 2003 Aug 18. Circulation. 2003. PMID: 12925454 Clinical Trial.
Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial.
Théroux P, Armstrong PW, Mahaffey KW, Hochman JS, Malloy KJ, Rollins S, Nicolau JC, Lavoie J, Luong TM, Burchenal J, Granger CB. Théroux P, et al. Among authors: rollins s. Eur Heart J. 2005 Oct;26(19):1964-70. doi: 10.1093/eurheartj/ehi292. Epub 2005 May 4. Eur Heart J. 2005. PMID: 15872036 Clinical Trial.
Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass.
Shernan SK, Fitch JC, Nussmeier NA, Chen JC, Rollins SA, Mojcik CF, Malloy KJ, Todaro TG, Filloon T, Boyce SW, Gangahar DM, Goldberg M, Saidman LJ, Mangano DT; Pexelizumab Study Investigators. Shernan SK, et al. Ann Thorac Surg. 2004 Mar;77(3):942-9; discussion 949-50. doi: 10.1016/j.athoracsur.2003.08.054. Ann Thorac Surg. 2004. PMID: 14992903 Clinical Trial.
Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass.
Fitch JC, Rollins S, Matis L, Alford B, Aranki S, Collard CD, Dewar M, Elefteriades J, Hines R, Kopf G, Kraker P, Li L, O'Hara R, Rinder C, Rinder H, Shaw R, Smith B, Stahl G, Shernan SK. Fitch JC, et al. Among authors: rollins s. Circulation. 1999 Dec 21-28;100(25):2499-506. doi: 10.1161/01.cir.100.25.2499. Circulation. 1999. PMID: 10604887 Clinical Trial.
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P, Röth A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM, Hill A, Schrezenmeier H, Fu CL, Maciejewski J, Rollins SA, Mojcik CF, Rother RP, Luzzatto L. Hillmen P, et al. Among authors: rollins sa. N Engl J Med. 2006 Sep 21;355(12):1233-43. doi: 10.1056/NEJMoa061648. N Engl J Med. 2006. PMID: 16990386 Free article. Clinical Trial.
151 results